FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma

World Journal of Gastroenterology

Volumn 21, Issue 7, 2015, Pages 2096-2101

  Guion Dusserre, Jean Florian ^a   Lorgis, Veronique ^a   Vincent, Julie ^a,b   Bengrine, Leila ^a   Ghiringhelli, Francois ^a,b  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

Bevacizumab; Biliary tract cancer; FOLFIRI; Intrahepatic cholangiocarcinoma; Second line treatment

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; MONOCLONAL ANTIBODY;

ADULT; AGED; ANEMIA; ARTICLE; BILE DUCT CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER MORTALITY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG TOXICITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EPISTAXIS; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; INFECTION; MALE; METASTATIC INTRAHEPATIC CHOLANGIOCARCINOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OFF LABEL DRUG USE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG EFFECTS; DRUG RESISTANCE; FRANCE; INTRAHEPATIC BILE DUCT; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; RADIOGRAPHY; SECONDARY; TIME FACTOR;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CAMPTOTHECIN; CHOLANGIOCARCINOMA; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; FRANCE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84922731282     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i7.2096     Document Type: Article

References (26)

1. Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007; 96: 896-902 [PMID: 17325704 DOI: 10.1038/sj.bjc.6603648]
2. Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, Nagakawa T, Nakayama T. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002; 95: 1685-1695 [PMID: 12365016 DOI: 10.1002/cncr.10831]
3. Henson DE, Albores-Saavedra J, Corle D. Carcinoma of the gallbladder. Histologic types, stage of disease, grade, and survival rates. Cancer 1992; 70: 1493-1497 [PMID: 1516000]
4. Glimelius B, Hoffman K, Sjödén PO, Jacobsson G, Sellström H, Enander LK, Linné T, Svensson C. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7: 593-600 [PMID: 8879373]
5. Thongprasert S. The role of chemotherapy in cholangiocarcinoma. Ann Oncol 2005; 16 Suppl 2: ii93-ii96 [PMID: 15958484 DOI: 10.1093/annonc/mdi712]
6. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362: 1273-1281 [PMID: 20375404 DOI: 10.1056/NEJMoa0908721]
7. Lee J, Park SH, Chang HM, Kim JS, Choi HJ, Lee MA, Jang JS, Jeung HC, Kang JH, Lee HW, Shin DB, Kang HJ, Sun JM, Park JO, Park YS, Kang WK, Lim HY. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2012; 13: 181-188 [PMID: 22192731 DOI: 10.1016/S1470-2045(11)70301-1]
8. Lamarca A, Hubner RA, David Ryder W, Valle JW. Second-line chemotherapy in advanced biliary cancer: a systematic review. Ann Oncol 2014; 25: 2328-2338 [PMID: 24769639 DOI: 10.1093/annonc/mdu162]
9. Cereda S, Belli C, Rognone A, Mazza E, Reni M. Secondline therapy in advanced biliary tract cancer: what should be the standard? Crit Rev Oncol Hematol 2013; 88: 368-374 [PMID: 23786845 DOI: 10.1016/j.critrevonc.2013.05.010]
10. Ramírez-Merino N, Aix SP, Cortés-Funes H. Chemotherapy for cholangiocarcinoma: An update. World J Gastrointest Oncol 2013; 5: 171-176 [PMID: 23919111 DOI: 10.4251/wjgo.v5.i7.171]
11. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247 [PMID: 19097774 DOI: 10.1016/j.ejca.2008.10.026]
12. Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, Nagino M, Kondo S, Nagaoka S, Funai J, Koshiji M, Nambu Y, Furuse J, Miyazaki M, Nimura Y. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 2010; 103: 469-474 [PMID: 20628385 DOI: 10.1038/sj.bjc.6605779]
13. Pracht M, Le Roux G, Sulpice L, Mesbah H, Manfredi S, Audrain O, Boudjema K, Raoul JL, Boucher E. Chemotherapy for inoperable advanced or metastatic cholangiocarcinoma: retrospective analysis of 78 cases in a single center over four years. Chemotherapy 2012; 58: 134-141 [PMID: 22572213 DOI: 10.1159/000337289]
14. Mir O, Coriat R, Dhooge M, Perkins G, Boudou-Rouquette P, Brezault C, Ropert S, Durand JP, Chaussade S, Goldwasser F. Feasibility of gemcitabine and oxaliplatin in patients with advanced biliary tract carcinoma and a performance status of 2. Anticancer Drugs 2012; 23: 739-744 [PMID: 22700002 DOI: 10.1097/CAD.0b013e3283556b9b]
15. Malka D, Cervera P, Foulon S, Trarbach T, de la Fouchardière C, Boucher E, Fartoux L, Faivre S, Blanc JF, Viret F, Assenat E, Seufferlein T, Herrmann T, Grenier J, Hammel P, Dollinger M, André T, Hahn P, Heinemann V, Rousseau V, Ducreux M, Pignon JP, Wendum D, Rosmorduc O, Greten TF. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliarytract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol 2014; 15: 819-828 [PMID: 24852116 DOI: 10.1016/S1470-2045(14)70212-8]
16. Bridgewater J, Palmer D, Cunningham D, Iveson T, Gillmore R, Waters J, Harrison M, Wasan H, Corrie P, Valle J. Outcome of second-line chemotherapy for biliary tract cancer. Eur J Cancer 2013; 49: 1511 [PMID: 23265701 DOI: 10.1016/j.ejca.2012.11.024]
17. Fornaro L, Cereda S, Aprile G, Di Girolamo S, Santini D, Silvestris N, Lonardi S, Leone F, Milella M, Vivaldi C, Belli C, Bergamo F, Lutrino SE, Filippi R, Russano M, Vaccaro V, Brunetti AE, Rotella V, Falcone A, Barbera MA, Corbelli J, Fasola G, Aglietta M, Zagonel V, Reni M, Vasile E, Brandi G. Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. Br J Cancer 2014; 110: 2165-2169 [PMID: 24714745 DOI: 10.1038/bjc.2014.190]
18. Brieau B, Dahan L, De Rycke Y, Boussaha T, Vasseur P, Tougeron D, Lecomte T, Coriat R, Bachet JB, Claudez P, Zaanan A, Soibinet P, Desramé J, Thirot-Bidault A, Trouilloud I, Mary F, Locher C, Marthey L, Cacheux W, Lievre A. Second-line chemotherapy for advanced biliary tract cancer after failure of gemcitabine plus platinum: Results of an AGEO multicenter retrospective study. J Clin Oncol 2014; 32: 5s
19. Normile D. Radiation safety. Accelerator leak halts Japanese physics experiments. Science 2013; 340: 1155 [PMID: 23744917 DOI: 10.1126/science.340.6137.1155]
20. Buzzoni R, Pusceddu S, Bajetta E, De Braud F, Platania M, Iannacone C, Cantore M, Mambrini A, Bertolini A, Alabiso O, Ciarlo A, Turco C, Mazzaferro V. Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study. Ann Oncol 2014; 25: 1597-1603 [PMID: 24827133 DOI: 10.1093/annonc/mdu175]
21. El-Khoueiry AB, Rankin C, Siegel AB, Iqbal S, Gong IY, Micetich KC, Kayaleh OR, Lenz HJ, Blanke CD. S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma. Br J Cancer 2014; 110: 882-887 [PMID: 24423918 DOI: 10.1038/bjc.2013.801]
22. Peck J, Wei L, Zalupski M, O'Neil B, Villalona Calero M, Bekaii-Saab T. HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib. Oncology 2012; 82: 175-179 [PMID: 22433475 DOI: 10.1159/000336488]
23. Yi JH, Thongprasert S, Lee J, Doval DC, Park SH, Park JO, Park YS, Kang WK, Lim HY. A phase II study of sunitinib as a secondline treatment in advanced biliary tract carcinoma: a multicentre, multinational study. Eur J Cancer 2012; 48: 196-201 [PMID: 22176869 DOI: 10.1016/j.ejca.2011.11.017]
24. Lubner SJ, Mahoney MR, Kolesar JL, Loconte NK, Kim GP, Pitot HC, Philip PA, Picus J, Yong WP, Horvath L, Van Hazel G, Erlichman CE, Holen KD. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J Clin Oncol 2010; 28: 3491-3497 [PMID: 20530271 DOI: 10.1200/JCO.2010.28.4075]
25. Zhu AX, Meyerhardt JA, Blaszkowsky LS, Kambadakone AR, Muzikansky A, Zheng H, Clark JW, Abrams TA, Chan JA, Enzinger PC, Bhargava P, Kwak EL, Allen JN, Jain SR, Stuart K, Horgan K, Sheehan S, Fuchs CS, Ryan DP, Sahani DV. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol 2010; 11: 48-54 [PMID: 19932054 DOI: 10.1016/S1470-2045(09)70333-X]
26. Riley E, Carloss H. Dramatic response to panitumumab and bevacizumab in metastatic gallbladder carcinoma. Oncologist 2011; 16: e1-e2 [PMID: 21586659 DOI: 10.1634/theoncologist.2008-0196]